Hyperphosphatemia ranked as area of greatest unmet need
Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden
Confirms patient preference for pills that are swallowed vs chewed
LOS ALTOS, Calif., July 26, 2022 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the results from an independent survey of renal dietitians conducted by Spherix Global Insights, an independent business intelligence firm that leverages its own independent data and expertise to provide strategic guidance. The survey canvassed 100 U.S. renal dietitians regarding a variety of topics related to the treatment of their chronic kidney disease and dialysis patients.
Key findings from the Spherix survey:
https://www.spherixglobalinsights.com/nephrology/bone-and-mineral-metabolism/
- Renal Dietitians (RDs) report the highest degree of influence on phosphate binder choice compared to other drug categories
- 9.2/10 vs. 7.8/10 for calcimimetics (2nd highest), and 1.9/10 for erythropoiesis-stimulating agents (ESAs)
- RDs indicate a high level of interest in the Renazorb product profile
- 66% indicate “high” interest
- 96% indicate “high” or “moderate” interest
- Most appealing aspects of Renazorb are Efficacy/Potency (47%) and Lower Number of pills (34%)
- 65% agree that patients prefer phosphate binders they can swallow as opposed to having to chew
- 65% of RDs rate hyperphosphatemia as the therapeutic area with the greatest unmet need for new products in dialysis patients
“As renal dietitians indicate they have high influence on brand selection for phosphate binders, the results of this survey are an important barometer that further support the potential for Renazorb to be the phosphate binder of choice,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “Renazorb, with its high and rapid phosphate binding and reduced pill burden for better medication compliance, should offer patients an enhanced treatment option while presenting significant commercial potential. Moving forward, we are focused on establishing our global commercial strategy for Renazorb as hyperphosphatemia is a growing medical need worldwide.”
